Radiopharm Theranostics
RADX
4 hedge funds and large institutions have $1.73M invested in Radiopharm Theranostics in 2025 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 1 closing their positions.
9% more capital invested
Capital invested by funds: $1.58M → $1.73M (+$148K)
0.35% less ownership
Funds ownership: 4.37% → 4.02% (-0.35%)
20% less funds holding
Funds holding: 5 → 4 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$41.9K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$2.36K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAA
Affinity Asset Advisors
New York
|
-$166K |
RADX Hedge Fund Activity: Q3 2025 in Review
4 of the 7,645 institutional investors tracked by Wall St. Rank reported a position in Radiopharm Theranostics (RADX) for Q3 2025, worth a combined $1.73M — up 9.4% from $1.58M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of RADX and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 2 added.
The largest buyer was PNC Financial Services Group, adding an estimated $41.9K. The largest seller was Affinity Asset Advisors, exiting entirely with an estimated $166K sold.
- 4 institutional investors held Radiopharm Theranostics (RADX) as of Q3 2025, down from 5 in Q2 2025.
- Funds reported $1.73M of Radiopharm Theranostics stock for Q3 2025, up 9.4% quarter-over-quarter.
- 0 funds opened new Radiopharm Theranostics positions in Q3 2025 and 1 closed out, a net change of -1 holder.
- The largest Radiopharm Theranostics buyer in Q3 2025 was PNC Financial Services Group, an estimated $41.9K added.
- The largest Radiopharm Theranostics seller in Q3 2025 was Affinity Asset Advisors, an estimated $166K sold.
Based on aggregated 13F filings for Q3 2025.